NCT04372407View on ClinicalTrials.gov

A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

September 29, 2020

Study Completion Date

January 19, 2021

Conditions
Healthy
Interventions
DRUG

Surufatinib

Surufatinib: 200 mg as single dose on Days 1 and 9

DRUG

Itraconazole

Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14

Trial Locations (1)

75247

Covance Clinical Research Unit, Dallas

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT04372407 - A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects | Biotech Hunter | Biotech Hunter